Long-term follow-up after authorization of gene therapy: leveraging real-world data
Publication date
2025-05
Authors
de Haart, Karin
Asao, Keiko
Ataher, Quazi
Geier, Jamie
Hillen, Jodie
Huang, Kui
Mol, Peter G M
Rivera, Donna
Wang, Huifen
Yang, Hong
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Gene therapies are innovative treatments that could revolutionize healthcare. Given their unique mechanisms of action, methods of manufacturing and administration, and the potential for long-lasting impact, gene therapies require long-term follow-up (LTFU) of safety and effectiveness post authorization, often using real-world data (RWD). With over 2000 gene therapies in development, there is a need for knowledge-building regarding LTFU studies. Here, we review regulatory, scientific, and operational requirements and considerations for LTFU studies using RWD from a global perspective. The insights in this review support post-authorization LTFU studies for gene therapies, thereby contributing to their safe and effective use.
Keywords
effectiveness, efficacy, gene therapy, long-term follow-up, pharmacoepidemiology, real-world data, safety
Citation
de Haart, K, Asao, K, Ataher, Q, Geier, J, Hillen, J, Huang, K, Mol, P G M, Rivera, D, Wang, H, Yang, H, Zhan, S, Hoogendoorn, W E & Bloem, L T 2025, 'Long-term follow-up after authorization of gene therapy : leveraging real-world data', Drug Discovery Today, vol. 30, no. 5, 104337. https://doi.org/10.1016/j.drudis.2025.104337